S-1: Windtree Therapeutics Faces Delisting, Pursues New Strategy

Windtree Therapeutics, Inc. has been delisted from Nasdaq, faces substantial doubt about its ability to continue as a going concern, and is pivoting to a new strategy focused on acquiring revenue-generating FDA-approved products.

Summary

• Windtree Therapeutics, Inc. (WINT) was delisted from the Nasdaq Capital Market on August 21, 2025, and now trades on The OTCID Basic Market under the symbol WINT.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern due to recurring losses, negative cash flows, and an accumulated deficit.
• A new corporate strategy was launched in January 2025 to become a revenue-generating biotech company through acquisitions of small companies with FDA-approved products, primarily using equity.
• The total number of authorized shares of capital stock was increased from 125,000,000 to 1,000,000,000 (995,000,000 common, 5,000,000 preferred) effective October 23, 2025, following stockholder approval on August 28, 2025.
• An Equity Line of Credit (ELOC) Purchase Agreement was entered into with Seven Knots, LLC on July 23, 2025, allowing the company to sell up to $500 million in common stock, with $50 million registered under this prospectus.
• The ELOC Purchase Agreement includes a $10 million Commitment Note issued to Seven Knots, convertible into 166,687,215 shares, and allows for the issuance of up to 555,555,556 Purchase Shares.
• Proceeds from VWAP Purchases under the ELOC are designated: 30% to repay outstanding indebtedness, then preferred stock redemption, and the balance for a Binance Coin Treasury Initiative (though this strategy was later terminated).
• On October 23, 2025, the ELOC Purchase Agreement was amended to expand the definition of 'Eligible Market' to include over-the-counter markets (OTCQX, OTCQB, OTC Pink Market).
• On October 9, 2025, $1.6 million in senior convertible promissory notes due 2026 were issued to institutional investors (including Seven Knots and Keystone Capital Partners, LLC), convertible at a 10% discount to the 20-day lowest sale price.
• The crypto treasury strategy, announced on July 16, 2025, involving a $60 million securities purchase agreement (Series E Preferred Stock and Warrants) with Build and Build, Corp., was subsequently terminated by management to focus on other businesses.
• The SEISMiC C clinical trial for istaroxime in severe cardiogenic shock was terminated after 20 enrollments due to limited resources, with the company now pursuing development in acute decompensated heart failure with its licensing partner, Lees Pharmaceutical (HK) Ltd.
• A dispute over a $3 million earnest money deposit for the Aubrey property was settled on September 30, 2025, with WINT LLC receiving $750,000 and the Purchase Agreement being terminated.

Sentiment

Score: 2

Explanation: The company is in a highly precarious financial position, evidenced by the Nasdaq delisting, going concern warning, and significant accumulated losses. While a new strategy and some positive clinical data exist, the ability to execute hinges on substantial, highly dilutive capital raises and successful partnerships, which carry high execution risk. The termination of a clinical trial and a new crypto strategy due to resource limitations further underscore the challenges.

Positives

• Istaroxime, the lead product candidate, has demonstrated significant improvement in systolic and diastolic cardiac function and was generally well tolerated in four Phase 2 clinical trials.
• Istaroxime has been granted Fast Track designation by the FDA for the treatment of Acute Heart Failure (AHF).
• Positive topline results from the Phase 2b SEISMiC Extension Study for istaroxime in SCAI Stage B cardiogenic shock showed significant improvement in systolic blood pressure and cardiac function, and improved pulmonary congestion and renal function.
• The company has secured an Equity Line of Credit (ELOC) for up to $500 million, providing a potential source of future capital.
• New patents have been granted for istaroxime and SERCA2a activators in various regions, extending intellectual property protection.
• The company has a new corporate strategy focused on acquiring revenue-generating FDA-approved products, which could diversify its business and provide a path to profitability.

Negatives

• The company's common stock was delisted from the Nasdaq Capital Market on August 21, 2025, and now trades on The OTCID Basic Market, which typically has lower liquidity and higher volatility.
• The company has incurred significant operating losses since its incorporation in 1992, with an accumulated deficit of $861.3 million as of June 30, 2025.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern for at least 12 months after the issuance of the financial statements.
• Cash and cash equivalents were critically low at $301 thousand as of June 30, 2025, with current liabilities of $15.7 million.
• The SEISMiC C clinical trial for istaroxime in severe cardiogenic shock was terminated after only 20 enrollments due to limited resources, indicating funding challenges for key development programs.
• The crypto treasury strategy, a new initiative announced in July 2025, was terminated by management, suggesting a lack of clear strategic direction or inability to execute on new ventures.
• The issuance of a large number of shares (up to 751,872,888) under the ELOC and Subject Notes will result in substantial dilution for existing stockholders.
• The company is currently ineligible to file new registration statements on Form S-3 until at least December 1, 2025, which may impair its ability to raise capital efficiently.

Risks

• A sale of a substantial number of shares of common stock by the selling stockholders could cause the price of common stock to decline.
• Future equity offerings and other issuances of securities will cause further dilution to existing stockholders.
• The company expects to require additional capital in the future and may not obtain sufficient financing on acceptable terms, potentially forcing delays or cessation of development activities.
• The current cash position, recurring losses, negative cash flows, and accumulated deficit raise substantial doubt about the company's ability to continue as a going concern.
• Indebtedness could adversely affect operating flexibility and financial condition, requiring a substantial portion of cash flows for payments.
• Reliance on third parties, primarily outside the U.S., to conduct preclinical studies and clinical trials exposes the company to risks of delays or failures in regulatory approval.
• The company relies on single suppliers for active pharmaceutical ingredients (APIs) and a single contract manufacturing organization (CMO) in China, posing supply chain risks.
• Product candidates are temperature sensitive and may have other attributes leading to limited shelf life, posing risks to supply, inventory, and waste management.
• The new corporate strategy to acquire small companies with FDA-approved products may not be successful due to identification, competition, regulatory approvals, or financing challenges.
• Operating results may fluctuate significantly due to various factors, making future results difficult to predict and potentially causing results to fall below expectations.
• The company could be adversely affected by any interruption, including cybersecurity breaches, in its ability to conduct business at its current locations or with third-party partners.
• The company is susceptible to litigation, including securities class actions, product liability claims, and patent infringement claims, which could harm financial performance.
• Activities are subject to various and complex laws and regulations, and violations could result in large civil and criminal penalties, debarment, and diversion of management time.
• Risks related to the collection and use of data, including personal information, could result in investigations, litigation, fines, and negative press.
• Healthcare reform measures in the U.S. and globally are expected to add pressure on financial expectations for product candidates, if approved.
• International operations subject the company to additional regulatory oversight, economic, social, and political uncertainties, including geopolitical tensions affecting supply lines.
• Intellectual property protection is uncertain, with core istaroxime patents expired and reliance on method-of-use patents, which may offer lesser protection.
• Patents covering product candidates could be found invalid or unenforceable if challenged, requiring significant time and money for defense.
• The Series C Certificate of Designation and July 2024 Warrants contain anti-dilution provisions that may increase the number of common shares issuable upon conversion/exercise, leading to further dilution.
• The Series C Preferred Stock has a liquidation preference senior to common stock, potentially reducing common stockholders' consideration in a liquidation event.
• Restrictive covenants in the PIPE Purchase Agreements may limit the company's ability to procure additional financing.

Future Outlook

The company expects to continue incurring operating losses for the foreseeable future and may never achieve or sustain profitability. Its ability to advance its corporate strategy is dependent on securing additional capital through public or private securities offerings, convertible debt financings, strategic transactions (including licensing agreements and collaborations), and potential grants. There is no assurance that sufficient funding will be obtained on acceptable terms. The company is actively pursuing partnerships for istaroxime (AHF and cardiogenic shock), preclinical heart failure programs, and the aPKCi oncology platform. Management is also considering diversifying the business into other revenue-generating sectors.

Management Comments

• Our management team has commercialization expertise in both large pharmaceutical and small biotech companies across multiple therapeutic areas, potentially enabling them to leverage synergies and optimize commercial performance across future subsidiaries.
• We believe there is an opportunity in the market: the acquisition of small companies with FDA-approved products from the many small biotech companies that struggle to maximize their commercialization potential.
• We believe that istaroxime has the potential to fulfill an unmet need in early and potentially more severe cardiogenic shock.
• We believe that the SEISMiC Extension and SEISMiC C studies have contributed to dose selection and to the characterization of the effects associated with SERCA2a activation and will support our clinical and regulatory strategy for istaroxime.
• Our decision to terminate the SEISMiC C study is related to our limited resources and our desire to advance the development of istaroxime into the broader acute heart failure space, and was not a result of any safety concerns with the SEISMiC C study.
• Company management made the decision not to move the cryptocurrency treasury strategy forward and to focus on other businesses in our new corporate strategy.

Industry Context

The biotechnology industry is highly competitive, characterized by rapid technological innovation and evolving standards. Many competitors possess greater resources and experience in product development, clinical trials, regulatory approvals, manufacturing, and marketing. The political and healthcare policy environment, including drug pricing reforms like the Inflation Reduction Act of 2022, is becoming more challenging, potentially reducing prices and reimbursement for approved products. The increasing scrutiny on foreign investment and geopolitical tensions (e.g., U.S.-China relations) also impact supply chains and capital attraction, particularly for companies relying on foreign manufacturers like Windtree. The company's new strategy to acquire small companies with FDA-approved products aims to capitalize on a market opportunity where smaller biotechs struggle with commercialization, a common challenge in the fragmented biotech landscape.

Comparison to Industry Standards

• The company's accumulated deficit of $861.3 million and recurring operating losses are significantly higher than typical development-stage biotechnology companies, indicating a prolonged period without profitability.
• The delisting from Nasdaq to The OTCID Basic Market is a severe adverse event, typically associated with companies failing to meet minimum listing standards, and is a significant deviation from the standard for publicly traded biotech firms.
• The termination of a Phase 2 clinical trial (SEISMiC C) due to resource limitations, despite positive interim data, is a notable setback compared to industry peers who typically aim to complete trials to maximize asset value.
• The reliance on a single supplier for APIs and a single CMO in China, as well as foreign clinical sites, exposes the company to higher supply chain and geopolitical risks compared to companies with diversified manufacturing and clinical operations.
• The company's strategy to acquire small companies with FDA-approved products is a common approach for struggling biotechs to pivot to revenue generation, but success is highly dependent on effective integration and commercialization, which can be challenging for companies with limited resources and a history of losses.
• The significant dilution from the ELOC and convertible notes, with potential for up to 96% dilution, is a substantial impact on existing shareholders, far exceeding typical capital raises in healthy biotech companies.

Management Changes

Corporate Governance

Legal Proceedings

• Not aware of any pending legal actions that would have a material adverse effect on business and operations.
• Potentially susceptible to litigation, including claims asserting violations of securities laws, product liability claims, and patent infringement claims.
• Settled a dispute regarding a $3 million earnest money deposit for the Aubrey property, with WINT LLC receiving $750,000 and the Purchase Agreement being terminated.

Related Party Transactions

• Lees Pharmaceutical Holdings Limited (and affiliates Lees (HK) and Zhaoke Pharmaceutical (Hefei) Co. Ltd.) has a regional licensed partnership for istaroxime, SERCA2a activators, and rostafuroxin in Greater China, with potential milestones up to $3.1 million and sales milestones up to $135.25 million, plus tiered royalties.
• Lees Pharmaceutical Holdings Limited (and affiliates Lees (HK) and Zhaoke Pharmaceutical (Hefei) Co. Ltd.) also has an Amended and Restated License, Development and Commercialization Agreement for KL4 surfactant products worldwide (excluding certain EU countries), with potential milestones up to $78.9 million and tiered royalties.
• A Project Financing Agreement with Lees (HK) for AEROSURF development resulted in $3.8 million liability balance as of June 30, 2025 and December 31, 2024, which the company is obligated to repay from future revenues.
• Panacea Venture Management Company Ltd. (and related party Panacea Venture Healthcare Fund I, L.P.) participated in a February 2023 warrant exercise inducement offer, resulting in $0.2 million gross proceeds to the company.
• Former CEO Craig E. Fraser and former CMO Steven G. Simonson, M.D. participated in the First Private Placement (PIPE) in July 2024, purchasing Series C Preferred Stock and July 2024 Warrants.

Stakeholder Impact

• Shareholders will experience significant dilution from the issuance of up to 751,872,888 shares of common stock under the ELOC and Subject Notes.
• Existing common stockholders' economic and voting interests will be diluted due to the increase in authorized shares and potential future equity issuances.
• The delisting from Nasdaq to the OTCID Basic Market will likely result in reduced liquidity and increased volatility for common stock, potentially making it less attractive to investors.
• The going concern warning raises significant uncertainty for all stakeholders regarding the company's long-term viability and ability to meet its obligations.
• Employees may face uncertainty due to the company's financial challenges and strategic shifts, including potential impacts on development activities and operational changes.
• Creditors and investors in preferred stock or convertible notes may have senior claims or specific redemption rights that could impact common stockholders in a liquidation scenario.

Next Steps

• Secure additional capital through public or private securities offerings, convertible debt financings, strategic transactions, and/or grants to fund operations and development programs.
• Pursue the new corporate strategy of acquiring small companies with FDA-approved products to become revenue-generating, utilizing equity for acquisitions.
• Seek partnerships to advance istaroxime for the treatment of Acute Heart Failure (AHF) globally, potentially joining Lees Pharmaceutical (HK) Ltd.'s Phase 3 study in China.
• Seek partnerships to support the continued study of istaroxime for cardiogenic shock.
• Seek partnerships to advance preclinical oral and intravenous SERCA2a activator heart failure compounds through preclinical studies towards IND submission.
• Seek partnerships to advance the aPKCi oncology platform through IND-enablement and into human testing, focusing initially on topical formulation for cutaneous malignancies.
• Enhance the product portfolio and leverage expertise by identifying additional product candidates that fit the market focus (specialty critical, acute care, orphan designation) and scale for development.
• Continue to evaluate and potentially modify the business strategy to respond to market developments and pursue other revenue-generating sectors.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by the Nasdaq delisting, a going concern warning from auditors, and a substantial accumulated deficit. While a new strategy to acquire revenue-generating assets is in place, its success is highly uncertain and dependent on further dilutive capital raises. The termination of a clinical trial due to resource limitations and the abandonment of a new crypto strategy highlight significant operational and financial challenges. The massive potential dilution from the ELOC and convertible notes, coupled with the stock trading on the less liquid OTC market, presents an extremely high risk for investors. The current financial state and the need for substantial, highly dilutive capital to merely continue operations make the stock a strong sell.

Keywords

Biotechnology, Pharmaceuticals, SEC Filing, S-1 Registration, Windtree Therapeutics, WINT, Cardiogenic Shock, Acute Heart Failure, Istaroxime, Rostafuroxin, SERCA2a Activators, aPKCi Inhibitor, Oncology, FDA Approval, Clinical Trials, Nasdaq Delisting, OTC Market, Equity Line of Credit, ELOC, Convertible Notes, Capital Raise, Dilution, Going Concern, Corporate Strategy, Intellectual Property, Risk Factors